Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521212 | 0.86 | MAPT (0.97) | MAPTKDM4ENPSR1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL18062870 | 0.85 | MAPT (0.58) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL7028984 | 0.82 | KDM4E (0.50) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL5681855 | 0.80 | NPSR1 (0.59) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL11742667 | 0.79 | NPSR1 (0.58) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL1284461 | 0.79 | NPSR1 (0.58) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL9866407 | 0.79 | NPSR1 (0.58) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL171627 | 0.79 | KDM4E (0.60) | MAPTKDM4ENPSR1HPGDPOLB | |
| SCHEMBL29773331 | 0.77 | KDM4E (0.62) | MAPTKDM4EHPGDPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL10002647 | 0.77 | MAPT (0.53) | MAPTKDM4ENPSR1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120156589-A1 | ELECTRODE CATALYST FOR FUEL CELL, MANUFACTURING METHOD THEREOF, AND FUEL CELL USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-06-21 | — | — | US | claimed |
| WO-2011099832-A2 | NOVEL BENZIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CRYSTALGENOMICS, INC. (KR) | 2011-08-18 | — | — | WO | claimed |
| WO-2010138084-A1 | CRYSTAL STRUCTURE OF CAP-FREE HUMAN eIF4E | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-12-02 | — | — | WO | claimed |
| EP-4733300-A1 | NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2026-04-29 | — | — | EP | disclosed |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | X-CHEM, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-12378463-B2 | Water-based resin with elasticity for applications in cementing and subterranean structures | SAUDI ARABIAN OIL COMPANY (SA) | 2025-08-05 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| WO-2024263007-A1 | NOVEL CHROMENE-BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-12-26 | — | — | WO | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4094/4885KDM4E 1828/4885NPSR1 264/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4095/4885KDM4E 1775/4885NPSR1 305/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | MAPT 890/4885KDM4E 2135/4885NPSR1 1515/4885 |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | MAPT 405/4885KDM4E 2888/4885NPSR1 4826/4885 |
| US-12606817-B2 | Methods of creating and screening DNA-encoded libraries | PCNA, DNA2, POLM | MAPT 2409/4885KDM4E 4406/4885NPSR1 3834/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | MAPT 341/4885KDM4E 2963/4885NPSR1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.